Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 12:55 AM
Ignite Modification Date:
2025-12-25 @ 12:55 AM
NCT ID:
NCT01660867
Brief Summary:
This is a prospective, randomized, controlled, double-blinded, clinical trial
Subject : 3mo \~ 24mo. aged infants with bronchiolitis
The effect of 3 % NaCl nebulizer or dexamethasone on admission rate of these infants in ED.
Detailed Description:
Randomly assigned to one of three groups
* Group I : nebulized epinephrine + 0.9% saline + placebo
* Group II : nebulized epinephrine + 3% saline + placebo
* Group III : nebulized epinephrine + 0.9% saline + dexamethasone
Group I received two treatments of nebulized epinephrine mixed 0.9% saline and a total of six oral doses of placebo, group II received nebulized epinephrine mixed 3% saline and oral placebo, and group III received nebulized epinephrine mixed 0.9% saline and oral dexamethasone.
The primary outcome is hospital admission within 7 days after the day of enrollment
Study:
NCT01660867
Study Brief:
Protocol Section:
NCT01660867